Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

6.22
+0.31505.34%
Post-market: 6.03-0.1850-2.98%19:30 EDT
Volume:81.99K
Turnover:493.98K
Market Cap:16.32M
PE:-0.35
High:6.41
Open:5.95
Low:5.74
Close:5.90
52wk High:10.75
52wk Low:1.31
Shares:2.63M
Float Shares:2.55M
Volume Ratio:0.92
T/O Rate:3.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.7100
EPS(LYR):-11.9306
ROE:-2011.66%
ROA:-40.08%
PB:-0.43
PE(LYR):-0.52

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:44 AM

Reuters
·
Jun 11

Adial Pharmaceuticals acquires Azora Therapeutics, lines up up to $64 million private placement

Reuters
·
Jun 11

Adial Pharmaceuticals - Enters Agreement for up to $64 Mln Private Placement

THOMSON REUTERS
·
Jun 11

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

THOMSON REUTERS
·
Jun 11

Adial Pharmaceuticals - Post-Deal: Adial Holders 7.7%, Azora Holders 51%, Investors 41.3% of Common Stock

THOMSON REUTERS
·
Jun 11

Adial Pharmaceuticals - Receives $32 Mln Upfront Financing for Pre-Funded Warrants at $2.75 Each

THOMSON REUTERS
·
Jun 11

Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained

TIPRANKS
·
May 14

Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending

Reuters
·
May 11

Press Release: Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

Dow Jones
·
May 11

Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk

TIPRANKS
·
May 10

Adial Pharmaceuticals Inc expected to post a loss of $1.21 a share - Earnings Preview

Reuters
·
May 09

Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate

Benzinga Earnings
·
May 09

Adial Pharmaceuticals Q1 net loss narrows 9% to $2.02 million

Reuters
·
May 09

Adial Pharmaceuticals files AD04 utility application with USPTO

TIPRANKS
·
Apr 30

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

GlobeNewswire
·
Apr 29

Adial submits AD04 application for FDA Commissioner's National Priority Voucher pilot program

Reuters
·
Apr 27

Adial Pharmaceuticals completes AD04 demonstration batch production

TIPRANKS
·
Apr 22

Adial completes AD04 demo batch, clearing path for planned Phase 3 trial

Reuters
·
Apr 22

Adial Pharmaceuticals Implements New Executive Equity Compensation Plan

TIPRANKS
·
Apr 10

Adial Pharma grants CEO Cary Claiborne 37,985 restricted stock awards

Reuters
·
Apr 10